CRSP CRISPR Therapeutics AG
2026Q2 · CUSIP H17182108 · Sector: Healthcare & Biotech
Fund flows are within the usual range
504 funds held CRSP at the end of 2026Q2, up 14 from the quarter before. Fund flows are within the usual range — nothing unusual. On the business itself, revenue over the last 12 months was $13M(YoY -64.8%), return on equity is -25.8%. CRSP has had 15 buying rushes in its history. It sits in the Healthcare & Biotech sector.
How many funds owned it, quarter by quarter
Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.
What happened after each past buying rush 15 times in its history
| Quarter of the rush | How unusual then | Price, next 3 months | Price, next 6 months |
|---|---|---|---|
| 2025Q4 | Top 20% | — | — |
| 2025Q2 | Top 10% | — | — |
| 2023Q4 | Top 10% | — | — |
| 2023Q2 | Top 10% | — | — |
| 2021Q2 | Top 5% | — | — |
| 2021Q1 | Top 20% | — | — |
| 2020Q4 | Top 5% | — | — |
| 2020Q3 | Top 10% | — | — |
These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.
Show all the numbers (large funds, value held, options…) ▾ Collapse ▴
These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.
8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.
Fundamentals
Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable
FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden
As of 2026-06-30 · SEC filings (XBRL)
Email me the next update
2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.